Clorox (CLX)
NYSEConsumer StaplesHousehold & Personal ProductsSnapshot 2026-11-04
$99.16+5.71%
Close 2026-11-04 · 1-day change
NYSEConsumer StaplesHousehold & Personal ProductsSnapshot 2026-11-04
Research Workspace
Put CLX beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Household Products is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Management is running behind on a stated commitment.
View ThesisManagement screens strong on capital allocation.
View ManagementExpectations look high — the market is pricing in about 39% growth a year, above the roughly 7% analysts expect, leaving little room for error.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskClorox's return to organic sales growth has to keep compounding to justify the price. Revenue grew 33% year over year in the latest quarter. The company also beat earnings estimates by 59.8%. It trades at 15x earnings versus a 16x peer median. The market is pricing in more growth than we forecast. Management is running behind on a stated commitment. Peer multiples imply a price about 33% below where it trades. The thesis is on watch. This read is provisional.
Trailing returns as of 2026-11-04. CLX is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 19 analysts currently covering CLX (as of Nov 2026).
Based on 8 Wall Street analysts offering 12-month price targets for CLX in the last 4 months.
Continue this research
Compare CLX with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| CLX Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 10 valuation methods, at three horizons. As of 2026-11-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Household Products — fair value, gap to price, and forward P/E.
Compare the value case
Put CLX next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Threatens: Return to organic sales growth and address sales decline
CEO comments signal macro headwinds for sales.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-11-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $99.16
The last 12 months of price, then the range of analyst 12-month targets from today’s $99.16.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 10% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Return to organic sales growth and improve market share
Guidance confirms return to organic growth despite cost headwinds.
Advances: Return to organic sales growth and address sales decline
Beating estimates supports return to organic growth.
Threatens: Manage gross margin through cost savings
Margin outlook cut signals cost savings insufficient to offset inflation.
Threatens: Manage gross margin through cost savings
Outlook trim on higher costs directly impacts margin objective.
Advances: Return to organic sales growth and address sales decline
Top-line beat supports organic growth recovery thesis.
Threatens: Manage gross margin through cost savings
Acknowledged challenging cost backdrop threatens margin stability.
Reuters reports a CEO appointment; leadership transition may affect execution, but no strategic or financial impact is specified.
